Rx only
Proctofoam HC Box and dispenser

About Proctofoam HC

A foam that offers no-touch application

Proctofoam HC provides effective relief from pain, swelling, and itching of the anal region with an anesthetic and anti-inflammatory-based foam. By prescription only.

Prescribe Proctofoam HC for relief of:

  • Hemorrhoids
  • Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the anal region

Proctofoam HC contains 2 active ingredients:

  • A topical anesthetic
  • An anti-inflammatory, vasoconstrictive corticosteroid

The only foam treatment

Proctofoam HC, the only foam product in the United States for treatment of anal pain, swelling, and itch:

Relief they can feel

  • Pramoxine hydrochloride's unique chemical structure is likely to minimize the danger of cross-sensitivity reactions in patients allergic to other anesthetics
  • Does not contain "caine" types of anesthetics

Dosing with no-touch Proctofoam HC

Proctofoam HC is applied to affected area(s) 3 to 4 times daily with the supplied applicator. No need for patients to touch sensitive areas with their finger.

Fragrance free

Reference: Proctofoam HC [package insert]. Somerset, NJ: Meda Pharmaceuticals Inc.; 2013.


Proctofoam HC is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the anal region.

More Important Safety Information

Topical corticosteroid products are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Instruct the patient not to insert any part of the aerosol container directly into the anus and avoid contact with the eyes.

Contents of the container are under pressure. Do not burn or puncture the aerosol container. Do not store in temperatures above 120°F (49°C).

If there is no evidence of clinical improvement within two weeks after starting Proctofoam-HC therapy, or if the patient’s condition worsens, discontinue the drug.

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

Patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, attempt to withdraw the drug, reduce the frequency of application, or substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen.

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

The following adverse reactions have been reported:

Burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For additional information, please see Full Prescribing Information.